Abstract
IMPORTANCE Dexamethasone 6 mg daily is recommended for up to 10 days in patients with severe and critical COVID-19, but a higher dose may benefit those with more severe disease.
OBJECTIVE To assess the effects of dexamethasone 12 mg versus 6 mg daily in patients with COVID-19 and severe hypoxia.
DESIGN, SETTING, PARTICIPANTS We conducted a parallel-grouped, stratified, blinded randomized trial including 1000 adults with confirmed COVID-19 receiving at least 10 l/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India from August 2020 to May 2021.
INTERVENTIONS Patients were randomized 1:1 to masked intravenous dexamethasone 12 mg or dexamethasone 6 mg daily for up to 10 days.
MAIN OUTCOME MEASURES The primary outcome was the number of days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) at 28 days. The primary analysis was adjusted for stratification variables (site, age below 70 years and invasive mechanical ventilation).
RESULTS After exclusion of 18 patients who withdrew consent, there were 982 patients (613 in Europe, 369 in India) in the intention-to-treat population. We had primary outcome data for 971 patients; 491 assigned to dexamethasone 12 mg and 480 assigned to dexamethasone 6 mg. The median number of days alive without life support was 22.0 days (interquartile range 6.0-28.0) in the 12 mg group and 20.5 days (4.0-28.0) in the 6 mg group (adjusted mean difference 1.3 days, 95% confidence interval (CI), 0.0-2.6; P=0.066). Mortality at 28 days was 27.1% and 32.3% in patients assigned to 12 mg and 6 mg, respectively (adjusted relative risk 0.86, 99% CI, 0.68-1.08). Serious adverse reactions, including septic shock and invasive fungal infections, occurred in 11.3% versus 13.2% of patients in the 12 mg group and 6 mg group, respectively (adjusted relative risk 0.85, 99% CI, 0.55-1.32).
CONCLUSIONS AND RELEVANCE Among patients with COVID-19 and severe hypoxia, dexamethasone 12 mg did not result in statistically significantly more days alive without life support at 28 days than dexamethasone 6 mg. However, the confidence interval around the point estimate should be considered when interpreting the results of this trial.
TRIAL REGISTRATION ClinicalTrials.gov (NCT04509973) and Clinical Trial Registry India (2020/10/028731).
Competing Interest Statement
MWM, AG, MBNK, MHM, TSM, GKV, MQJ, JWL, TBJ, CMK, ECC, CJSH, TSJ, LSH, ERBB, RZ, MMC, SA, EVH, TSA, EGA and AP are affiliated to Dept. of Intensive Care at Rigshospitalet, which has received grants from The Novo Nordisk Foundation during the conduct of the trial; and grants from Pfizer, Fresenius Kabi, and The Novo Nordisk Foundation outside the submitted work. TB reports grants from Novo Nordisk Foundation, grants from Simonsen Foundation, grants and personal fees from GSK, grants and personal fees from Pfizer, personal fees from Boehringer Ingelheim, grants and personal fees from Gilead, personal fees from MSD, grants from Lundbeck Foundation, grants from Kai Hansen Foundation, personal fees from Pentabase ApS, grants from Erik and Susanna Olesens Charitable Fund, all outside the submitted work. CSU has received grants and personal fees from GSK, personal fees from Astra Zeneca, personal fees from TEVA, grants and personal fees from Sanofi Genzyme, grants, personal fees and non-financial support from Boehringer-Ingelheim, personal fees and non-financial support from Novartis, personal fees from OrionPharma, personal fees from Chiesi, all outside the submitted work. JVD has received personal fees (paid to his institution), from Edwards India, outside the submitted work VJ has received grants and personal fees from Baxter Healthcare, personal fees from Astra Zeneca, Visterra, Chinook, NephroPlus, all outside the submitted work BV and NEH have received grants from Baxter outside the submitted work. LC and SMJ are affiliated to Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, which has received grants from Edwards Lifesciences Services GmbH, Phagenesis Limited, Nestle, all outside the submitted work. PRA has received personal fees from CIPLA, personal fees from Dr. Reddy's Laboratories, personal fees from Abbott Nutrition and personal fees from Sanofi, all outside the submitted work. All other authors declare no competing interests.
Clinical Trial
ClinicalTrials.gov (NCT04509973)
Clinical Protocols
https://onlinelibrary.wiley.com/doi/10.1111/aas.13795
Funding Statement
Funding/Support: This trial was funded by the Novo Nordisk Foundation and supported by the Research Council at Rigshospitalet. Role of the Funder/Supporter: Neither the funder nor the supporter had roles in the design of the protocol, trial conduct, or the analyses or reporting of the data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial protocol was approved by the Ethics Committee of the Capital Region of Denmark and institutionally at each trial site
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* These authors led the set up and conduct of the trial in India
Data Availability
Fully de-identified data will be available 1-year after the publication of the trial data upon application to the Management Committee
